Lecture 14: Drug Development and Biosimilars Flashcards

1
Q

What Constitutes a “Drug”?

A

A drug is a substance that produces change in cellular or physiologic functioning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Drug development influenced by:

A

High cost of research; complex regulatory environment & legislations;
insurer reimbursements; and patient perspectives

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Some of factors that influence drug development include

A
 Development cost (~ $1.3 - $2.8 billion or more) and time (can be as much as or >15 years)
 Regulatory approval process
 Changes in laws
 Patient acceptance
 Insurance reimbursement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Investing in new drug development is

A

expensive and risky

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

FDA Regulates drugs under two legislative acts

A
  • Food, Drug, and Cosmetic Act – for small molecule drugs

- Public Health Service Act – for biologicals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The FDA’s mission is to promote and protect the public health by promoting:

A

safe and effective products reach the market in a timely safe and effective products reach the market in a timely way
- However: once FDA determines a drug is safe and effective, it has little control over
its use in medical practice, such as for non-approved indications (“off-label” use)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Specific FDA Function/Role in Drug Development

Process and Drugs in the Marketplace

A
  • Approves drugs on the basis of purity, safety, efficacy
  • Regulate all labeling of prescription and nonprescription drugs
  • Advertising OTCs the responsibility of the Federal Trade Commission (FTC)
  • Regulate manufacturing processes of drugs and institution of drug recalls
  • Regulate bio-equivalence for generics and bio-similars
  • Monitor safety of US blood supply
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Conceptualization

A

performed by independent investigators, small research companies, academic institutions & large pharmaceutical companies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Intramural

A

NIH investigators perform research

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Extramural

A

independent investigators win research grants to perform research

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Drug development has

A

3 stages prior to approval

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

STAGE 1

A

Drug discovery
Discovery ( Laboratory based)

5,000 – 10,000 compounds may be synthesized and tested
- 250 “may” make it to pre-clinical testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

STAGE 2

A

Pre-clinical Testing

  • Tests performed to determine if candidate molecule safe to test in humans
  • Candidates for drugs are first tested in animals
  • Very few candidate materials for drugs make it through pre-clinical testing
  • < 0.1% of potential candidate drugs go from discovery to clinical testing stage
  • Varies in number of years it takes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

STAGE 3

A

Clinical testing has 3 DISTINCT PHASES with distinct goals
- Investigational New Drug (IND) application must be submitted to FDA
in order to begin clinical testing in humans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

STAGE 4

A

Post approval and post clinical testing (also called Phase IV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

To begin clinical testing,

A

Investigational New Drug (IND) Application must be filed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

When all clincial testing is complete,

A

The New Drug Application (NDA) must be filed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

PHASE IV

A

addition research post-marketing by FDA

- Used to identify events not detected during clinical testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

IND

A

Investigational New Drug

20
Q

NDA

A

New Drug Application

21
Q

3 phases before drug approval : Clinical testing

A
  • Phase 1: Learn how the drug works in (small number) of humans – set dosage
  • Phase II: Demonstrate efficacy (proof of concept) and safety (toxicity) in patients
  • Phase III: Provide strong evidence of efficacy and safety by studying candidate drug
    in a few thousand people with target disease in randomized, controlled trials using
    doses and settings more like “real world” practice
22
Q

Phase I Clinical Testing Goals Include

A
  • Learn how candidate drug works in HEALTHY humans
     Studies of <100 healthy individuals
     Establish dose range, metabolism, excretion, toxicities
     Usually takes one year or less to complete
23
Q

Phase II Clinical Testing Goals Include

A
  • Study candidate drug in a few hundred people with target disease
  • Efficacy (proof of concept) and safety (toxicity) in patients
  • Single arm studies (No comparison group)
  • Usually takes up to two years to complete
    (occurs after Phase I testing is completed)
24
Q

Phase III Clinical Testing Goals Includ

A

Study a few thousand people with target disease in randomized, controlled trials
 Strong evidence for efficacy and safety
 Use doses and settings more like real-world practice
 Success is necessary to move to the next stage of approval
 Usually takes three to four years to complete
(occurs after Phase I and Phase II testing is completed

25
Efficacy
Extent to which a specific intervention, procedure, regimen, or service produces a beneficial result under ideal conditions  “Ideal conditions” are achieved in clinical trials
26
Effectiveness
- Measure of success of a therapeutic intervention carried out in a typical environment on typical patients - “real-world” conditions
27
Post-Clinical testing
NDA submitted to FDA upon successful completion of clinical testing (Stage 3)  NDA specifies the following information about the candidate drug:  Manufacturing  Action in the body  Marketing  Labeling and toxicologic information
28
Phase IV testing and evaluation
Post-marketing surveillance in larger samples and for longer time frame  evaluation of safety and effectiveness not detected in earlier trials  “real-world” settings, “real-world” patients, and very large numbers of people
29
MedWatch
- FDA’s safety information adverse event reporting program  Health professionals encouraged to report adverse events in their patients  Manufacturers are required to report adverse events to FDA
30
Adverse Event Reporting System
Supports the FDA's post-marketing safety surveillance program  Contains adverse drug event reports FDA received from manufacturers required by regulation
31
ANDA
Abbreviated New Drug Application
32
Abbreviated New Drug Application (ANDA). What is ANDA
- submitted to FDA for a drug already “approved” but required when requesting:  Change from prescription to over-the-counter status  Change in ingredients, dosage, manufacturing, formulation, or labeling
33
Who submits to ANDA
Manufacturers of generics or biosimilars - FDA examines the bio-equivalence, bioavailability, and pharmacokinetic/pharmacodynamic properties
34
Intellectual Property (IP) rights
protect innovators & provide incentives for drug development But: allow Pharma Companies to have a monopoly & charge higher prices
35
Drug Price Competition & Patent Term Restoration Act of 1984 | (Hatch Waxman Act) & PPACA
Key legislation concerned with patent protection & promoting generics -
36
Hatch-Waxman Act Characteristics
- Applies to small molecule drugs Innovator data exclusivity for 5 years from FDA approval*  Additional 3 years of data exclusivity for new indications  Additional 6 months of exclusivity for pediatric applications  No new clinical trials required for generics (ANDA)  Regulation pertains to small-molecule drugs
37
Hatch-Waxman Act
established the approval pathway for generic drug products, under which applicants can submit an abbreviated new drug application (ANDA)
38
Biologic
are a large, new part of the Rx marketplace - Very important uses in major diseases  Very, VERY expensive medications
39
Majority of Biologicals Use Living Cells to | Produce a Protein Product
Insert gene encoding the protein of interest  Cells require proper conditions for optimal growth (temp, pH, oxygen, feeds, etc.)  Culture and fermentation can take weeks  Complex Purification Steps  Safe product with desired potency
40
Small molecule drugs vs. Biological drugs
Biological drugs are large and have a high MW. They are complex. Produced in living cell structure. Unstable and immunogenic Small molecule drugs are non-immunogenic, stable, produced by chemical synthesis
41
BLA
Biologic License Application- which includes | - Manufacturing info to demonstrate company can properly and consistently manufacture the product
42
The biological product is licensed and can be marketed in the US only if:
FDA determines that the data shows the biological product is safe and effective for it's proposed use, and -the biological product can be manufactured in a way that ensures a quality product
43
Biologics Price Competition and Innovation Act (2009) Abbreviated approval pathway in place under the 2010 Patient Protection and Affordable Care Act (PPACA)
Allows for licensing with less than full complement of pre-clinical and clinical data  Focus on the manufacturing process  “highly similar” with no clinically significant differences in safety, purity, potency, immunogenicity  Tested against a reference product, NOT against placebo!  “The goal is not to independently establish safety & effectiveness of proposed product
44
Biosimilarity”
A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness [purity, potency] from the reference product Only minor differences in clinically inactive components are allowable in biosimilar products”
45
Interchangeable means
An interchangeable biological product may be substituted for the reference product by a pharmacist without the intervention of the health care provider who prescribed the reference product -They have different brand names, making their identification more confusing